Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Gesamtmark- und Lymphoidbestrahlung vor Spendertransplantation und Cyclophosphamid bei der Behandlung von Patienten mit akuter myeloischer Leukämie

30. September 2026 aktualisiert von: City of Hope Medical Center

Pilotstudie zur Konditionierung durch Totalmark/Lymphoidbestrahlung (TMLI) vor allogener hämatopoetischer Stammzelltransplantation (HCT), gefolgt von Cyclophosphamid-basierter Graft-versus-Host-Disease-Prophylaxe nach der Transplantation bei akuter myeloischer Leukämie in vollständiger Remission

This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone marrow and blood, instead of applying radiation to the whole body. Giving total bone marrow and lymphoid irradiation before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving total bone marrow and lymphoid irradiation before donor transplant and cyclophosphamide after transplant may work better at treating acute myeloid leukemia.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To evaluate the safety/feasibility of combining a total marrow and lymphoid irradiation (TMLI) transplant conditioning regimen with a post-transplant high dose cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis strategy, through the assessment of: adverse events: type, frequency, severity, attribution, time course, duration and complications: including acute GvHD, infection and delayed neutrophil/platelet engraftment.

SECONDARY OBJECTIVES:

I. To estimate the cumulative incidence (CI) of acute GvHD at 100 days post allogeneic hematopoietic cell transplantation (alloHCT).

II. To estimate the CI of chronic GvHD at 6 months, 1- and 2-years post alloHCT.

III. To estimate GVHD-free relapse-free survival (GRFS) at 1- and 2-years post alloHCT.

IV. To describe the kinetics of immune reconstitution and T cell repertoire in the first year post alloHCT.

V. To estimate overall survival (OS), relapse-free survival (RFS) and CI of relapse, and non-relapse mortality (NRM) at 100 days, 1- and 2-years post alloHCT.

VI. To characterize quality of life using 36-Item Short Form Health Survey (SF-36), Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and M. D. Anderson Symptom Inventory (MDASI) or Pediatric Quality of Life Inventory (PedsQL) at 100 days, 6 months, 1- and 2-years post alloHCT.

VII. To assess bone marrow cellularity from bone marrow samples. VIII. To assess the clonogenic potential of cells from bone marrow samples. IX. To assess stromal damage from bone marrow samples. X. To evaluate cytokines and oxidative stress markers.

OUTLINE: This is a dose-escalation study of TMLI.

Patients undergo TMLI twice daily (BID) on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide intravenously (IV) over 2 hours on days 3 and 4, tacrolimus given by continuous intravenous infusion (CIV) on days 5-90, and filgrastim beginning on day 5 until absolute neutrophil count (ANC) is at least 1,500/mm^3 for 3 consecutive days.

After completion of study treatment, patients are followed for up to 24 months.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

56

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • Duarte, California, Vereinigte Staaten, 91010
        • City of Hope Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

16 Jahre bis 60 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • This study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)
  • Karnofsky performance status (KPS) >= 70%
  • The effects of radiation on the developing fetus are known to be teratogenic; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  • Patients with acute myelogenous leukemia (AML) who are in first or second complete remission
  • All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques; (red cell exchange or plasma exchange)
  • A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
  • Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 70 ml/min as calculated by the Cockcroft-Gault formula
  • A bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease
  • Patients should also have a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
  • Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value
  • All subjects must have the ability to understand and the willingness to sign a written informed consent; signed informed consent form approved by the Institutional Review Board (IRB) is required; the patient, family member, and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting, all pertinent information with respect to risks and benefits to the donor and recipient will be presented; alternative treatment modalities will be discussed
  • The time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days
  • Prior therapy with etoposide and cyclophosphamide is allowed
  • DONOR: donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)

Exclusion Criteria:

  • Patients should not have any uncontrolled illness including ongoing or active or poorly controlled infection
  • Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; maintenance therapy with Food and Drug Administration (FDA)-approved targeted therapies (e.g. tyrosine kinase inhibitors for Philadelphia chromosome [Ph] positive [+] acute lymphoblastic leukemia [ALL], and FLT inhibitors for FLT3+ patients) will be allowed after day 60 disease assessment
  • Prior radiation therapy that would exclude the use of TMLI
  • Relapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously
  • Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
  • Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
  • Patients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollment
  • Patients with other active malignancies are ineligible for this study, other than localized malignancies
  • Patients that are pregnant or breastfeeding
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to, infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.
  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment (TMLI, cyclophosphamide)

Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.

Correlative studies

Ancillary studies

Andere Namen:
  • Bewertung der Lebensqualität

Given IV

Andere Namen:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamid
  • 2H-1,3,2-Oxazaphosphorin, 2-[Bis(2-chlorethyl)amino]tetrahydro-, 2-Oxid, Monohydrat
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamid
  • Cicloxal
  • Clafen
  • Claphene
  • CP-Monohydrat
  • CYCLO-Zelle
  • Cycloblastin
  • Cyclophospham
  • Cyclophosphamid-Monohydrat
  • Cyclophosphamid
  • Cyclophosphan
  • Cyclophosphanum
  • Cyclostin
  • Cytophosphan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmun
  • Syklofosfamid
  • WR-138719

Ancillary studies

Undergo alloHCT

Andere Namen:
  • Allogene hämatopoetische Zelltransplantation
  • Allogene Stammzelltransplantation
  • HSC
  • HSCT
  • Stammzelltransplantation, allogen

Administer according to City of Hope standard operating procedures

Andere Namen:
  • G-CSF
  • r-metHuG-CSF
  • Neupogen
  • Rekombinanter menschlicher Methionyl-Granulozyten-Kolonie-stimulierender Faktor
  • rG-CSF
  • Tevagrastim

Given CIV

Andere Namen:
  • Prograf
  • Hekoria
  • FK506
  • Fujimycin
  • Prothema

Undergo TMLI

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
1a. Incidence of adverse events
Zeitfenster: Up to 24 months

Assessed using Bearman Scale Regimen-Related Toxicity scale. Scale range: Grade 0-4 (increasing grade reflects increasing severity), where Grade 0-none/did not experience and Grade 4=death.

Up to 24 months
1b. Incidence of adverse events
Zeitfenster: Up to 24 months

Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale. Scale range: Grade 1-5 (increasing grade reflects increasing severity), where Grade 1 reflects a more milder form of the adverse event and Grade 5=death.

Up to 24 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Zeit bis zur Erholung/Verpflanzung von Neutrophilen und Blutplättchen
Zeitfenster: Vom Tag 0 bis zur Genesung oder Erklärung des Transplantationsversagens, bewertet bis zu 24 Monate
Vom Tag 0 bis zur Genesung oder Erklärung des Transplantationsversagens, bewertet bis zu 24 Monate
Beurteilung der Restschädigung des Knochenmarks
Zeitfenster: Bis zu 24 Monate
Bis zu 24 Monate
Zytokine
Zeitfenster: Bis zu 24 Monate
Bis zu 24 Monate
Marker für oxidativen Stress
Zeitfenster: Bis zu 24 Monate
Bis zu 24 Monate
Acute graft versus host disease (GvHD)
Zeitfenster: Day 0 to 100 (120) days post-transplant

Graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999).

Day 0 to 100 (120) days post-transplant
Chronic GVHD
Zeitfenster: From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months

The first day of chronic GvHD onset will be used to calculate cumulative incidence curves, with relapse/death prior to onset considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999).

From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
GvHD-free/relapse-free survival (GRFS)
Zeitfenster: From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months

Will be calculated using the Kaplan-Meier method.

From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
Levels of immune cells
Zeitfenster: Up to 24 months

Will be measured by flow cytometry for cell subsets: a. T-cells.

Up to 24 months
Levels of immune cells
Zeitfenster: Up to 24 months

Will be measured by flow cytometry for cell subsets: b. B-cells.

Up to 24 months
Levels of immune cells
Zeitfenster: Up to 24 months

Will be measured by flow cytometry for cell subsets: c. natural killer (NK) cells.

Up to 24 months
Levels of immune cells
Zeitfenster: Up to 24 months

Will be measured by flow cytometry for cell subsets: d. regulatory T cells (T-regs).

Up to 24 months
Overall survival
Zeitfenster: From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months

Will be calculated using the Kaplan-Meier method.

From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
Relapse-free survival
Zeitfenster: From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months

Will be calculated using the Kaplan-Meier method.

From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
Relapse
Zeitfenster: From start of therapy, assessed up to 24 months

Will be calculated using the competing risk method as described by Gooley et al. (1999).

From start of therapy, assessed up to 24 months
Non-relapse mortality (NRM)
Zeitfenster: From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months

The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. Will be calculated using the Kaplan-Meier method and the competing risk method as described by Gooley et al. (1999).

From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
Quality of life -Questionnaire
Zeitfenster: Up to 24 months

Assessed using a. 36-Item Short Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

The eight sections are:

  • a1. vitality
  • a2. physical functioning
  • a3. bodily pain
  • a4. general health perceptions
  • a5. physical role functioning
  • a6. emotional role functioning
  • a7. social role functioning
  • a8. mental health
Up to 24 months
Quality of life-Function Assessment
Zeitfenster: Up to 24 months

Assessed using b. Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). (FACT-BMT) is a 47-item, valid and reliable measure of five dimensions of quality of life in bone marrow transplant patients. The dimensions collected and assessed are:

  • b1.physical well being
  • b2. Social and family well being
  • b3. Emotional well being
  • b4. Functional well being
  • b5. Additional concerns.
Up to 24 months
Quality of life -Symptom Inventory
Zeitfenster: Up to 24 months

Assessed using c. M. D. Anderson Symptom Inventory (MDASI). MDASI is a multi-symptom patient-reported outcome (PRO) measure for clinical and research use. Use the MDASI to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. The following parameters will be reported:

  • c1a. Pain
  • c1b. Fatigue
  • c1c. Nausea
  • c1d. Disturbed sleep
  • c1e. Distress/feeling upset
  • c1f. Shortness of breath
  • c1g. Difficulty remembering
  • c1h. Lack of appetite
  • c1i. Drowsiness
  • c1j. Dry mouth
  • c1k. Sadness
  • c1l. Vomiting
  • c1m. Numbness/tingling
  • c1n. Walking
  • c1o. Activity
  • c1p. Working (including housework)
  • c1q. Relations with other people
  • c1r. Enjoyment of life
  • c1s. Mood A total of eight quality of life parameters will be reported on each pediatric transplant patient.
  • c2a.Pain and Hurt
  • c2b. Fatigue and Sleep
  • c2c. Nausea
  • c2d. Worry
  • c2e. Nutrition
  • c2f. Thinking
  • c2g. Communication
Up to 24 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Anthony S Stein, City of Hope Medical Center

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. März 2018

Primärer Abschluss (Geschätzt)

12. April 2027

Studienabschluss (Geschätzt)

12. April 2027

Studienanmeldedaten

Zuerst eingereicht

22. Februar 2018

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. März 2018

Zuerst gepostet (Tatsächlich)

16. März 2018

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 17423
  • 17423 (Andere Kennung: City of Hope Comprehensive Cancer Center)
  • NCI-2018-00177 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .